Seasonality appeared in the effectiveness of IL12/23 and IL17 inhibitor therapy in moderate to severe psoriasis, with better results obtained within the first months of treatment in patients starting therapy in the warm period of the year (May–September). No seasonality was observed in patients treated with TNF-α inhibitors. Here, TNF is linked to psoriasis.